AdvancedAdvT Reports Full-Year Trading Ahead of Market Expectations

AdvancedAdvT’s pre-close update: another beat and stronger margins

AdvancedAdvT Limited (AIM: ADVT) has posted a pre-close trading update for the year ending 28 February 2026, and it’s a tidy step ahead of market expectations. Revenue and adjusted EBITDA both beat consensus, margins have nudged higher again, and recurring revenue remains the bedrock of the model.

For retail investors, the message is simple: steady execution, better-than-expected profitability, and a sizeable cash pile that keeps options open.

Key numbers at a glance: revenue, EBITDA, margins and cash

Metric	FY26 (pre-close)	FY25	Market consensus (FY26)
Revenue	Approximately £53.0 million	£43.3 million	Approximately £52.5 million
Adjusted EBITDA	Not less than £14.4 million	£11.3 million	Approximately £13.7 million
Adjusted EBITDA margin	Over 27%	26%	Not disclosed
Recurring revenue mix	Approximately 80%	Not disclosed	Not applicable
Cash balance (28 Feb 2026)	Approximately £96.0 million	Not disclosed	Approximately £96.0 million
Investments during the year	Circa £15.0 million	Not disclosed	Not applicable

That revenue implies roughly 22% year-on-year growth, with adjusted EBITDA up by at least around 27%. The beat versus consensus is modest on revenue (about £0.5 million) and more meaningful on EBITDA (at least £0.7 million), which underscores the margin work flowing through.

What’s driving the outperformance

Recurring revenue and retention doing the heavy lifting

AdvancedAdvT reports approximately 80% of revenue as recurring. In plain English, that’s contracted or subscription-like income that rolls in each period, offering visibility and stability. The update also flags “excellent customer retention” across both divisions, which supports low churn and strengthens lifetime value. Exact retention metrics are not disclosed, but the language and the 80% mix point to a sticky customer base.

Margin expansion from operational improvements

Adjusted EBITDA margins are now over 27%, up from 26% last year and approximately 21% in the Group’s first reporting period. That’s a clear trend of operational tightening and scale benefits. Adjusted EBITDA refers to earnings before interest, tax, depreciation and amortisation, adjusted for items management considers non-recurring or non-core. It’s a common profitability measure in software, and this steady climb suggests the portfolio is being tuned effectively.

Two focus areas: business solutions & healthcare compliance, and HCM

The Group’s software sits in two transformation lanes: business solutions and healthcare compliance, and human capital management (HCM). These are regulated, mission-critical workflows where switching can be painful for customers and reliability matters. That positioning helps explain the recurring mix and retention strength.

AI commentary: amplifier, not a disruptor, for this portfolio

Executive Chair Vin Murria is clear on the role of AI here: in AdvancedAdvT’s markets, AI “acts as an amplifier” of platform value rather than a threat. In practice, that means productivity gains for customers, a potentially larger addressable market, and greater importance on trusted, compliant software. It also fits the company’s stated capability set around AI, data analytics and business intelligence.

My take: that’s a sensible framing for software embedded in regulated, workflow-heavy environments. The risk of disruption never fully disappears, but with systems of record that are deeply integrated, the balance of probabilities tilts toward enhancement rather than displacement.

Cash and investment firepower

Cash is expected to be approximately £96 million at year-end, in line with market expectations. The Group also notes circa £15 million of investments during the year. The update doesn’t break down what those investments comprise, and there’s no comment on net cash or debt positions – not disclosed.

Strategically, the note to editors reiterates that AdvancedAdvT is developing both organically and through acquisitions, expanding across adjacent markets and geographies. With this cash balance, the company has room to invest in product, tuck-in deals, or both, subject to discipline and returns.

Why this update matters for investors

• Beating expectations: Even small beats are positive signals in software, especially when paired with margin expansion.
• Quality of revenue: Approximately 80% recurring revenue and “excellent” retention underpin predictability and cash generation.
• Operating discipline: Margins now over 27% show the portfolio is scaling sensibly.
• Optionality: Approximately £96 million of cash provides flexibility for further investment and M&A, consistent with strategy.

On the flip side, there are a few watchpoints. The company hasn’t disclosed segmental revenue, net cash, or detailed outlook metrics in this update. The size and nature of the circa £15 million investments are also not specified. For a fuller picture, the audited results and narrative will matter.

What to watch for in the full-year results

• Revenue split and growth drivers by division – business solutions & healthcare compliance versus HCM.
• Retention and churn data – quantified metrics to back up “excellent customer retention”.
• Annual recurring revenue (ARR) or billings – not disclosed today, but helpful for visibility.
• Cash deployment plans – clarity on pipeline for acquisitions, product investment, or potential returns to shareholders. No dividend or buyback is mentioned in this update.
• AI-led enhancements – examples of how AI is improving customer productivity and monetisation.
• Outlook commentary – guidance or qualitative colour for FY27 is not disclosed here.

The RNS does not specify the date for the full-year results publication.

My bottom line: steady execution, sensible positioning

This is a tidy pre-close from AdvancedAdvT. Revenue growth of approximately 22%, margin progress to over 27%, and an EBITDA beat suggest the operating playbook is working. The “systems of record” positioning in regulated, mission-critical workflows naturally lends itself to sticky, recurring income – and that’s exactly what the numbers reflect.

With approximately £96 million of cash and a stated appetite for organic and acquisitive growth, the company has options. The next set of audited numbers should fill in the blanks on divisional performance, retention metrics and capital allocation. For now, the direction of travel is positive, and the business looks well placed to keep compounding through operational improvements and disciplined execution.